ARTICLE | Emerging Company Profile

Unum: Universal chimeras

How Unum aims to broaden use of T cell therapies and improve their safety

October 27, 2014 7:00 AM UTC

Unum Therapeutics Inc.'s ACTR platform offers an approach for generating controllable T cell therapies that could be safer and applicable to a broader range of cancers than CAR- and TCR-based immunotherapies.

The company debuted last week with a $12 million series A round co-led by Atlas Venture and Fidelity Biosciences. The round will fund Phase I testing of a lead ACTR T cell therapeutic that binds to a marketed antibody...